Abstract
The interaction of hexokinase with mitochondria has emerged as a powerful mechanism in protecting many cell types against cell death. However, the role of mitochondrial hexokinase (mitoHK) in cardiac ischemia-reperfusion injury has as of yet received little attention. In this review we examine whether increased binding of hexokinase to the mitochondrion is also an integral component of cardioprotective signalling. We discuss observations in cardiac mitochondrial activation that directed us to the hypothesis of hexokinase cellular redistribution with reversible, cardioprotective ischemia, summarize the data showing that many cardioprotective interventions, such as ischemic preconditioning, insulin, morphine and volatile anesthetics, increase mitochondrial hexokinase binding within the intact heart, and discuss similarities between mitochondrial hexokinase association and ischemic preconditioning. Although most data indicate that mitochondrial hexokinase may indeed be an integral part of cardioprotection, a definitive proof for a causal relation between the amount of mitoHK and cardiac ischemia-reperfusion injury in the intact heart is eagerly awaited. When such relationship is indeed observed, the association of hexokinase with mitochondria will offer an opportunity to develop new therapies to combat ischemic cardiac diseases.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Chiari F, Castellaro D, Marin O, Petronilli V, Brusilow WS, Juhaszova M, Sollott SJ, Forte M, Bernardi P, Rasola A (2008) PLoS ONE 3:e1852
Clarke SJ, Khaliulin I, Das M, Parker JE, Heesom KJ, Halestrap AP (2008) Circ Res 102:1082–1090
Cross HR, Opie LH, Radda GK, Clarke K (1996) Circ Res 78:482–491
Da-Silva WS, Gómez-Puyou A, de Gómez-Puyou MT, Moreno-Sanchez R, De Felice FG, de Meis L, Oliveira MF, Galina A (2004) J Biol Chem 279:39846–39855
Garlid KD, Paucek P, Yarov-Yarovoy V, Murray HN, Darbenzio RB, D’Alonzo AJ, Lodge NJ, Smith MA, Grover GJ (1997) Circ Res 81:1072–1082
Green DR, Kroemer G (2004) Science 305:626–629
Gürel E, Smeele KM, Eerbeek O, Koeman A, Demirci C, Hollmann MW, Zuurbier CJ (2009) J Appl Physiol. doi:10.1152/japplphysiol.90537.2008
Hattori R, Maulik N, Otani H, Zhu L, Cordis G, Engelman RM, Siddiqui MA, Das DK (2001) J Mol Cell Cardiol 33:1929–1936
Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM (2005) Am J Physiol Heart Circ Physiol 288:H971–H976
Jennings RB, Sebbag L, Schwartz LM, Crago MS, Reimer KA (2001) J Mol Cell Cardiol 33:1571–1588
Liang Q, Donthi RV, Kralik PM, Epstein PN (2002) Cardiovasc Res 53:423–430
Lopaschuk GD, Wambolt RB, Barr RL (1993) J Pharmacol Exp Ther 264:135–144
Majewski N, Nogueira V, Robey RB, Hay N (2004a) Mol Cell Biol 24:730–740
Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, Chandel NS, Thompson CB, Robey RB, Hay N (2004b) Mol Cell 16:819–830
Miyamoto S, Murphy AN, Brown JH (2008) Cell Death Diff 15:521–529
Murphy E, Steenbergen C (2008) Physiol Rev 88:581–609
Murry CE, Jennings RB, Reimer KA (1986) Circulation 74:1124–1136
Pastorino JG, Hoek JB (2003) Curr Med Chem 10:1535–1551
Pastorino JG, Hoek JB (2008) J Bioenerg Biomembr 40:171–182
Pastorino JG, Hoek JB, Shulga N (2005) Cancer Res 65:10545–10554
Pedersen PL (2008) J Bioenerg Biomembr 40:123–126
Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH (2002) Biochim Biophys Acta 1555:14–20
Robey RB, Hay N (2005) Cell Cycle 4:654–658
Sack MN (2006) Cardiovasc Res 72:210–219
Santiago APSA, Chaves EA, Oliveira MF, Galina A (2008) Biochimie 90:1566–1577
Sun L, Shukair S, Naik TJ, Moazed F, Ardehali H (2008) Mol Cell Biol 28:1007–1017
Tong H, Chen W, Steenbergen C, Murphy E (2000) Circ Res 87:309–381
Treberg JR, MacCormack TJ, Lewis JM, Almeida-Val VMF, Val AL, Driedzic WR (2007) Physiol Biochem Zool 80:542–550
Van Beek JHGM, Tian X, Zuurbier CJ, de Groot B, Van Echteld CJA, Eijgelshoven MHJ, Hak JB (1998) Mol Cell Biochem 184:321–344
Van der Heiden MG, Chandel NS, Schumacker PT, Thompson CB (1999) Mol Cell 3:159–167
Vogt AM, Poolman M, Ackermann C, Yildiz M, Schoels W, Fell DA, Kübler W (2002) J Biol Chem 277:24411–24419
Wilson JE (1995) Rev Physiol Biochem Pharmacol 126:65–198
Wilson JE (2003) J Exp Biol 206:2049–2057
Ye G, Donthi RV, Metreveli NS, Epstein PN (2005) Cardiovas Toxicol 5:293–300
Zuurbier CJ, Van Beek JH (1997) Circ Res 81:69–75
Zuurbier CJ, Ince C (2002) Pflügers Arch 443:908–916
Zuurbier CJ, Van Wezel HB (2008) Cardiovasc Drugs Ther 22:125–131
Zuurbier CJ, Eerbeek O, Goedhart PT, Struys EA, Verhoeven NM, Jacobs C, Ince C (2004) Cardiovasc Res 62:145–153
Zuurbier CJ, Eerbeek O, Meijer AJ (2005) Am J Physiol Heart Circ Physiol 289:H496–H499
Zuurbier CJ, Keijzers PJM, Koeman A, Van Wezel HB, Hollmann MW (2008) Anesth Analg 106:135–142
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Zuurbier, C.J., Smeele, K.M.A. & Eerbeek, O. Mitochondrial hexokinase and cardioprotection of the intact heart. J Bioenerg Biomembr 41, 181–185 (2009). https://doi.org/10.1007/s10863-009-9209-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10863-009-9209-7